Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Enrolling by invitation · Phase 2 · Has a placebo group
Conditions studied: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
In brief
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Key facts
- Study ID
- NCT02402660
- Run by
- Alkeus Pharmaceuticals, Inc.
- People needed
- 160
- Starts
- 2015-08-01
- Expected to finish
- 2026-11-30
- Last updated by the study team
- 2025-04-27
Who can join
Age: 8 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Alkeus Site — Phoenix, Arizona, United States
- Alkeus Site — Los Angeles, California, United States
- Alkeus Site — Aurora, Colorado, United States
- Alkeus Site — Gainesville, Florida, United States
- Alkeus Site — Miami, Florida, United States
- Alkeus Site — Indianapolis, Indiana, United States
- Alkeus Site — Baltimore, Maryland, United States
- Alkeus Site — Grand Rapids, Michigan, United States
- Alkeus Site — New York, New York, United States
- Alkeus Site — Westbury, New York, United States
- Alkeus Site — Houston, Texas, United States
- Alkeus Site — Salt Lake City, Utah, United States
- Alkeus Site — Silverdale, Washington, United States
- Alkeus Site — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.